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Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). 
The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged 
CP/CPPS patients.
Methods: Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin 
(group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of 
Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International 
Index of Erectile Function-5 (IIEF-5) were used to grade the patients’ symptoms and the quality of life impact at the start of the 
study, and at 4 and 8 weeks from the initiation of the study.
Results:  There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of 
the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined 
via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined 
via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not signifi-
cant. There was no statistically significant difference in residual urine.
Conclusions: Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and 
the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the soli-
fenacin treatment group.
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INTRODUCTION
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is 
an enigma in urology although it is a common disorder [1]. Be-
cause it is diagnosed only on the basis of symptoms, principally 
pain or discomfort in the pelvic region [2], it may not be treated 
adequately. Although pain is the most severe and commonly 
reported symptom in patients with CP/CPPS, many patients 
have lower urinary tract symptoms (LUTS), especially storage 
symptoms, such as frequency and urgency [3-6].
  Among the most commonly used treatments for CP/CPPS 
are antibiotics, α-blockers, and anti-inflammatory drugs. Anti-
cholinergic agents are used to treat frequency and urgency; how-
ever, the role of anticholinergics in the management of CP/CPPS 
is unknown, and there are few references on the topic [7].
  The aim of this study was to evaluate the prevalence of LUTS 
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and the efficacy of solifenacin in a prospective, randomized, 
single-blinded, multi-centered clinical trial of young and mid-
dle-aged CP/CPPS patients. 
MATERIALS AND METHODS
This study was performed under the Institutional Review Board 
approval of each clinical trial center, and written informed con-
sent was given by all patients. At four Korean centers, a total of 
96 patients with CP/CPPS were randomly assigned into group 
1 (n=49; ciprofloxacin 1,000 mg once daily) or group 2 (n=47; 
ciprofloxacin 1,000 mg and solifenacin 5 mg once daily) with 
single blinded randomization method. All patients had a urine 
analysis, urine culture, expressed prostatic secretions examina-
tion, prostate-specific antigen (PSA) measurement, uroflowme-
try, and postvoid residual volume (PVR) measurement. The In-
ternational Prostate Symptom Score (IPSS), the National Insti-
tutes of Health Chronic Prostatitis Symptom Index (NIH-CP-
SI), and the International Index of Erectile Function-5 (IIEF-5) 
were used to grade the patients’ symptoms and the quality of 
life (QoL) impact at the starting point (baseline) and at 4 and 8 
weeks into the study. 
  Patients aged 20 to 49 years were included to exclude the 
LUTS of benign prostatic hyperplasia (BPH). Other inclusion 
criteria were patients diagnosed with CP/CPPS (NIH-CPSI cat-
egory IIIa and IIIb) and with pelvic pain for 3 or more months, 
negative urine culture and expressed prostatic secretion results, 
PVR of 100 mL or less, maximum urinary flow rate (Qmax) of 
15 mL/sec or greater, a total NIH-CPSI score of 8 or greater, 
and an NIH-CPSI pain score of 4 or greater at baseline. Exclu-
sion criteria included a history of previous prostate surgery, 
5α-reductase inhibitor use for 3 or more months, anticholiner-
gic use within 6 months of baseline, PSA level of 4.0 ng/mL or 
more, prostatic cancer, urethral stricture, diabetes mellitus, neu-
rogenic bladder and hypersensitivity to ciprofloxacin (1,000 
mg) or solifenacin.
  Statistical analysis was performed by repeated-measures anal-
ysis of variance with SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), 
and P<0.05 was considered to indicate significance.
RESULTS
There was no significant difference between group 1 and 2 at the 
baseline when the age, duration of disease, PVR, Qmax, scores 
on the IPSS, NIH-CPSI or IIEF-5 were compared. Among those 
patients, 67.4% demonstrated LUTS (IPSS ≥ 8). In NIH-CPSI 
score, there were statistically significant differences between 
group I and II in total (12.1±7.4 vs. 10.8±5.4, P=0.01), pain 
(5.3±3.6 vs. 13.9±5.0, P=0.04) and urinary domain scores 
(1.9±1.6 vs. 2.1±1.8, P=0.01) at 8 weeks of treatment. Where-
as after 8weeks of treatment, there was no statistical differences 
in QoL scores between group I and II: 5.1±3.0 vs. 5.1±1.8, 
P=0.13 (Table 1). Statistically significant differences were found 
in the IPSS total score and storage domain score between group 
I and II at 8 weeks of treatment. IPSS total score was 5.3±5.5 
and 7.2±4.7 (P=0.04), and the storage was 2.0±2.2 and 
3.2±2.3 (P=0.01), respectively. Also, these scores were signifi-
cantly decreased compared to the baseline scores. Even though, 
voiding scores (3.4±3.7 vs. 4.0±3.2, P=0.22) and QoL scores 
(1.7±1.2 vs. 2.4±1.4, P=0.38) were decreased from the mean 
scores during 8 weeks of treatment, there was no statistical dif-
ferences (Table 2). The total score of the IIEF-5 was increased 
without any significant statistical differences (Table 3).
DISCUSSION
CP/CPPS is a common disorder in men, and the syndrome is 
diagnosed only on the basis of symptoms, principally pain or 
discomfort in the pelvic region. Because the pathophysiology of 
Table 1. Comparison of the NIH-CPSI results in the pre-treat-
ment and post-treatment groups
 
NIH-CPSI
Baseline 4 wk 8 wk
Group 1 (n=40)
Total 19.8±6.4 14.5±7.6 12.1±7.4
Pain 9.3±3.2 6.5±3.9 5.3±3.6
Urinary 2.9±2.2 2.2±1.9 1.9±1.6
QoL 7.8±3.0 6.1±3.3 5.1±3.3
Group 2 (n=47)
Total 22.4±6.0 13.9±5.0 10.8±5.4
a)
Pain 9.4±3.3 5.1±3.0 3.9±2.9
a)
Urinary 4.9±2.6 2.8±2.2 2.1±1.8
a)
QoL 8.4±2.7 6.1±2.6 5.1±1.8
Values are presented as mean±SD.
NIH-CPSI, National Institutes of Health chronic prostatitis symptom 
index; QoL, quality of life.
Group 1: antibiotics alone. Group 2: antibiotics and solifenacin (5 mg).
a)Indicates a significant difference from group 1 (P<0.05) by repeated 
measure analysis of variance.174    www.einj.or.kr
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the disease has not been established, antimicrobial agents are 
frequently used. However a patient who does not respond to 
antibiotics might need additional treatments, such as nonsteroi-
dal anti-inflammatory drugs, alpha-blocking agents, or other 
therapies for symptomatic relief [1, 8]. 
  Dmochowski and Gomelsky [9] suggested that CP/CPPS was 
another condition with prominent LUTS. The condition is typi-
cally accompanied by pain with ejaculation or in the perineal 
area. Because there is no gold standard diagnostic test for CP/
CPPS and because its etiology is largely unknown, this entity 
remains a diagnosis of exclusion. As with BPH, the symptoms 
of CP/CPPS can be present during the storage phase, can be pres-
ent during the voiding phase, or can occur postmicturition [9].
  A recent study showed that because CP/CPPS is an important 
multifactorial problem that affects men of all ages and demo-
graphic subgroups, patients with CP/CPPS receive many empir-
ical therapies. The three most common treatments prescribed 
by physicians are antimicrobial agents, anti-inflammatory medi-
cines, and alpha-adrenergic receptor antagonists [10]. Many 
theories exist on the efficacy of the medicines prescribed; how-
ever, there remains a lack of scientific evidence to prove their ef-
ficacy [11]. Therefore, there is a need for a long-term, random-
ized, controlled study to evaluate the efficacy of treatment, espe-
cially because controversy concerning the efficacy and mecha-
nism of action of alpha-blockers in the treatment of CP/CPPS. 
  Furthermore, many studies have investigated the efficacy of 
antimicrobial agents and alpha-adrenergic receptor antagonists, 
but there have been few studies of the efficacy of other medicines 
used in empirical treatment, such as plant extracts, zinc, antide-
pressants, anti-anxiety medications, 5-alpha reductase inhibi-
tors, narcotics, analgesics, anticholinergics, or antispasmodics.
  In recent reports, the primary symptoms of CP/CPPS were 
pelvic pain and frequent urination [4,6,12].
  However, many physicians have used anticholinergics empir-
ically for treatment, and there are only introductions to treat-
ment with anticholinergics in some of the guidelines [7].
  In this study, to evaluate the prevalence of LUTS and the effi-
cacy of anticholinergics, we used the IPSS, NIH-CPSI, and IIEF- 
5 to grade the symptoms and QoL impact. In our study, only 
young and middle-aged patients were included to exclude the 
LUTS of BPH because BPH patients have a higher prevalence 
of LUTS than do healthy men and a higher prevalence of sex-
related symptoms [13]. In the present study, we found statisti-
cally significant differences between the two groups in the total 
score, pain domain, and urinary domain of the NIH-CPSI and 
the total score and storage symptom score of the IPSS. In a re-
cent study investigating treatment of CP/CPPS with alfuzosin, 
alfuzosin improved only the voiding symptom score determined 
via the IPSS and not the storage symptoms assessed by the IPSS 
or any of the domains in the NIH-CPSI [14], Such finding pro-
vide the basis for believing that combined therapy with alpha-
blockers and anticholinergics may show synergistic effects in 
the management of CP/CPPS. The IPSS assessment appears to 
be a good indicator for follow-up in the management of CP/
CPPS, especially in patients with severe LUTS [12]. Solifenacin 
improved the pain associated with CP/CPPS in our study, but 
we think that this was probably because some patients with in-
terstitial cystitis were included in the study.  
  Our data suggests that anticholinergics are effective in the 
management of CP/CPPS, especially for the treatment of storage 
Table 2. Comparison of the IPSS results in the pre-treatment 
and post-treatment groups
 
NIH-CPSI
Baseline 4 wk 8 wk
Group 1 (n=40)
Total 9.0±8.3 6.6±5.2 5.3±5.5
Storage 3.3±3.2 2.6±2.5 2.0±2.2
Voiding 5.7±5.5 4.0±4.2 3.4±3.7
QoL 2.7±1.6 2.1±1.5 1.7±1.2
Group 2 (n=47)
Total 13.5±7.1 9.0±5.3 7.2±4.7
a)
Storage 5.9±2.7 4.0±2.5 3.2±2.3
a)
Voiding 7.5±5.0 5.0±3.9 4.0±3.2
QoL 3.5±1.6 2.9±1.5 2.4±1.4
Values are presented as mean±SD.
IPSS, International Prostate Symptom Score; QoL, quality of life.
Group 1: antibiotics alone. Group 2: antibiotics and solifenacin (5 mg).
a)Indicates a significant difference from group 1 (P<0.05) by repeated 
measure analysis of variance.
Table 3. Comparison of the IIEF results in the pre-treatment and 
post-treatment groups
 
NIH-CPSI
Baseline 4 wk 8 wk
Group 1 (n=40) Total 17.3±5.2 17.6±5.6 17.2±5.8
Group 2 (n=47) Total 17.8±4.9 18.1±5.6 18.2±5.9
Values are presented as mean±SD.
IIEF-5,  International Index of Erectile Function-5.
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symptoms. However, because the number of patients was small 
and the period of the clinical trial was short, more randomized, 
controlled, long-term and large-scale clinical trials are needed. 
  In our study, the scores between the two groups were com-
pared. However, to prove the effective of anticholinergics in CP/
CPPS, absolute decreased values between two groups should be 
considered during the study.
  In conclusion, many CP/CPPS patients had LUTS. Solifena-
cin demonstrated efficancy in CP/CPPS in improving the NIH-
CPSI and the IPSS total score and storage score. Storage factors 
improved significantly, as determined via the NIH-CPSI and 
IPSS in the solifenacin treatment group.
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